蛋白氨酸酸酶1B (PTP1B) 功能,结构和抑制策略,用于开发抗糖尿病药物
Andrea Coronell-Tovar1, Juan P Pardo1, Adela Rodríguez-Romero2
1Laboratorio de Biosensores y Modelaje molecular, Departamento de Bioquímica, Facultad de Medicina, Universidad Nacional Autónoma de México, Ciudad de México, Mexico.
FEBS letters
|May 9, 2024
概括
蛋白氨酸酸酶1B (PTP1B) 是代谢,糖尿病和肥胖的关键. 抑制PTP1B具有治疗潜力,但开发选择性抑制剂仍然是一个重大挑战.
科学领域:
- 生物化学 生化学
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 氨酸蛋白酸酶非受体1型 (PTP1B) 是代谢调节中的关键酶,影响胰岛素和瘦素敏感性.
- PTP1B在2型糖尿病和肥胖症的发展中起着重要作用.
- 它在这些疾病中的参与使得PTP1B成为抗糖尿病,抗肥胖和潜在的抗癌疗法的验证分子标.
研究的目的:
- 审查自1988年孤立以来PTP1B研究的进展.
- 为了提供更广泛的蛋白质氨酸酸酶 (PTP) 家族的背景.
- 概述PTP1B在糖尿病和肥胖中的作用,并讨论开发抑制剂的挑战.
主要方法:
- 对PTP1B研究和PTP家族的文献综述.
- 分析PTP1B在新陈代谢中的生理作用.
- 检查不同的PTP1B抑制策略 (正,全,双,基因沉默).
主要成果:
- PTP1B与胰岛素和瘦素抵抗有关,这对2型糖尿病和肥胖症至关重要.
- 有四种主要的策略可以抑制PTP1B.
- 开发强效,选择性和生物可利用的PTP1B抑制剂面临相当大的障碍.
结论:
- PTP1B是代谢疾病的关键目标.
- 尽管有治疗前景,但在抑制剂开发方面存在挑战.
- 需要进行进一步的研究,以克服有效向PTP1B的选择性,功效和细胞透性的限制.
相关概念视频
Transducer Mechanism: Enzyme-Linked Receptors
2.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.4K
Protein Kinases and Phosphatases
13.1K
Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
13.1K
Glucagon-like Receptor Agonists
318
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
318
Dipeptidyl Peptidase 4 Inhibitors
181
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
181
Insulin: The Receptor and Signaling Pathways
1.2K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
1.2K
Oral Hypoglycemic Agents: Biguanides and Glitazones
192
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
192


